Начало › Рак на белия дроб с недребноклетъчен тип › Тексас › Tyler
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в Tyler, TX
20 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около Tyler (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Набиране на участнициФаза 3
- The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0148), Tyler
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Набиране на участнициФаза 1
- Exelixis Clinical Site #70, Tyler
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 1/2
- Research Site, Tyler
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Набиране на участнициФаза 3
- Texas Oncology - Northeast Texas, Tyler
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 3
- Texas Oncology-Northeast Texas, Tyler
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Texas Oncology - Northeast Texas, Tyler
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- The University of Texas Health Science Center at Tyler, Tyler
- Texas Oncology - Northeast, Tyler
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Набиране на участнициФаза 3
- The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center, Tyler
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Texas Oncology - Northeast Texas /ID# 272000, Tyler
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Набиране на участнициФаза 3
- Texas Oncology - Northeast Texas, Tyler
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Набиране на участнициФаза 3
- Clinical Study Site, Tyler
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Набиране на участнициФаза 2/3
- Local Institution - 007-890-A, Tyler
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- University of Texas Health Center at Tyler, Tyler
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Набиране на участнициФаза 1
- Texas Oncology, P.A. - Oncology, Tyler
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- University of Texas at Tyler, Tyler
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Набиране на участнициФаза 1/2
- Texas Oncology - Northeast, Tyler
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Набиране на участнициФаза 1/2
- Texas Oncology - Northeast TX, Tyler
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Набиране на участнициФаза 1/2
- The University of Texas Health Science Center at Tyler, Tyler
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Набиране на участнициФаза 1
- UT Health East Texas HOPE Cancer Center, Tyler
- UT Health East Texas Hope Cancer Center, Tyler
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Набиране на участнициФаза 1
- Texas Oncology - Tyler, Tyler
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY120 проучвания
- Arlington, VA104 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Columbus, OH56 проучвания
- Washington, DC55 проучвания
Други проучвания в Tyler
- Болест на Крон16 проучвания
- Язвенен колит14 проучвания
- Колоректален рак8 проучвания
- Сърдечна недостатъчност8 проучвания
- Рак (всички видове)7 проучвания
- Рак на яйчниците7 проучвания
- Ендометриален рак6 проучвания
- Плоскоклетъчен карцином на главата и шията6 проучвания
- Рак на гърдата6 проучвания
- Метастатичен рак5 проучвания
- Възпалително заболяване на червата5 проучвания
- Хронична лимфоцитна левкемия5 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.